Evidence map›Paper›PMID 41808878›Full record

ArticleRespiratory medicine case reports2026

Synchronous occurrence of interstitial lung disease and ICANS after tarlatamab initiation in recurrent small-cell lung cancer.

Masakazu Takahara, Atsuto Mouri, Ou Yamaguchi, Tatsuhiko Uno, Kosuke Hashimoto, Hisao Imai, Hiroshi Kagamu, Kyoichi Kaira

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masakazu TakaharaDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Atsuto MouriDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Ou YamaguchiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Tatsuhiko UnoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Kosuke HashimotoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Hisao ImaiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Kyoichi KairaDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tarlatamab has been approved for patients with recurrent extensive-stage small-cell lung cancer (ES-SCLC). However, it is associated with adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Limited data exist on the concurrent occurrence of ICANS and other treatment-related adverse events. In our case study, we observed the synchronous occurrence of interstitial lung disease (ILD) and ICANS following tarlatamab initiation in recurrent ES-SCLC.

Indexed as

Adverse eventsICANSInterstitial lung diseaseSCLCTarlatamab

Identifiers

PMID41808878
PMCPMC12969449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.